Last reviewed · How we verify

NCT03255148

Influence of Oxytocin on Resting State Neurophysiological Measures

Completed Phase 1 Last updated 1 August 2019
What this trial tests

Phase 1 trial testing Oxytocin in Oxytocin in 56 participants. Completed in 18 May 2018.

Timeline
24 July 2017
Primary endpoint
18 May 2018
18 May 2018

Quick facts

Lead sponsorKU Leuven
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposebasic science
Enrollment56
Start date24 July 2017
Primary completion18 May 2018
Estimated completion18 May 2018
Sites1 location across Belgium

Drugs / interventions tested

Conditions studied

Sponsor

KU Leuven — full company profile →

Who can join

Adults 18 to 38, male only, with Oxytocin. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, the investigators will explore the influence of oxytocin administration on several neurophysiological responses (EEG, skin conductance and heart rate) during rest.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Oxytocin

Trials testing the same drug.

Other recruiting trials for Oxytocin

Currently open trials in the same condition.

Other KU Leuven trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03255148.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing